Navigation Links
China Kanghui Holdings Announces Participation in Upcoming Investor Conferences
Date:6/2/2011

CHANGZHOU, China, June 2, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH) ("Kanghui" or the "Company"), a leading domestic developer, manufacturer and marketer of orthopedic implants in China, today announced its participation in the following investor events:

  • Jefferies 2011 Global Healthcare Conference to be held on June 6-9, 2011 at the Grand Hyatt in New York City.  Management is scheduled to present on June 6 at 3:00 p.m. and meet with institutional investors throughout the day.
  • Goldman Sachs' 32nd Annual Global Healthcare Conference to be held on June 6 - 9, 2011 at the Terranea Resort in Rancho Palos Verdes, California. Management is scheduled to meet with institutional investors throughout June 8 – 9.

  • About China Kanghui HoldingsFounded in 1997, Kanghui is a leading domestic developer, manufacturer and marketer of orthopedic implants in China. The Company offers a wide array of proprietary orthopedic implant products in trauma and spine. It has an extensive network of distributors for its products in China. In addition, Kanghui's products are distributed in 24 countries. Kanghui has strong research and development capabilities, focused on developing new proprietary products, including new product lines, extensions of existing product lines and enhancements of existing products. For more information, please visit http://ir.kanghui.com.Contact:Asia Bridge Capital LimitedSusan Stillings+1-415-800-4428susan.stillings@asiabridgegroup.comCarene Toh+86-186-1835-6339carene.toh@asiabridgegroup.com
    '/>"/>

    SOURCE China Kanghui Holdings
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
    (Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
    (Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
    Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
    ... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
    ... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
    Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
    (Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
    (Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
    (Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
    (Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
    (Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
    Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
    ... Prevention Toolkit, a collection of resources designed to ... interacting with HIV-positive patients. The goal is ... risk and decrease the spread of HIV. ... AIDS Prevention Studies, includes proven prevention interventions for ...
    ... performing a hysterectomy is common practice to prevent the ... performed in 55 percent of all US women having ... article in the March/April issue of t Philadelphia, PA, ... oophorectomy) while performing a hysterectomy is common practice to ...
    ... with key beliefs and male monogamy , TUESDAY, March ... atheists tend to have higher IQs than those who are ... IQs also seem to make men less likely to cheat. ... fidelity than men with lower IQs, although the same association ...
    ... drugs in the pipeline, review finds , TUESDAY, March ... studies published in major medical journals answer the fundamental ... works best for a particular condition. , So concludes ... where experts seek to determine which available medicine is ...
    ... disease, CDC says, upping risks for transmitting it to others, ... one in six Americans is infected with herpes simplex virus ... of the most common sexually transmitted diseases (STDs) in the ... lifetime, causing recurrent and painful genital sores, according to the ...
    ... ... , , ... 9, 2010 -- More than 15.7 million women are HIV positive world-wide. In fact one ... States is diagnosed with HIV . These statistics underline the critical need for women and ...
    Cached Medicine News:Health News:New study questions benefits of elective removal of ovaries during hysterectomy 2Health News:Do Liberals, Atheists Have Higher IQs? 2Health News:Do Liberals, Atheists Have Higher IQs? 3Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 2Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 3Health News:Herpes Infects One in Six in U.S. 2Health News:Herpes Infects One in Six in U.S. 3Health News:Herpes Infects One in Six in U.S. 4Health News:Herpes Infects One in Six in U.S. 5Health News:March 10 is National Women and Girls with HIV/AIDS Awareness Day 2Health News:March 10 is National Women and Girls with HIV/AIDS Awareness Day 3
    Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
    ... designed specifically for posteror segment surgical procedures. ... fluid. A high pressure luer lock tubing ... 8in (20cm) long. ID - .02in (.50mm); ... with standing injections of viscoelastic fluids. 30G ...
    ... specifically for posteror segment surgical procedures. For ... A high pressure luer lock tubing set ... (20cm) long. ID - .02in (.50mm); OD ... standing injections of viscoelastic fluids. 30G (.30mm) ...
    ... Product designed specifically ... procedures.Designed for injection of ... viscous fluids. Special high ... to thinwall cannula. May ...
    Medicine Products: